- Home
- FE vs BIIB Comparison
FE vs BIIB Comparison
Compare FE & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FE
- BIIB
- Stock Information
- Founded
- FE 1996
- BIIB 1978
- Country
- FE United States
- BIIB United States
- Employees
- FE N/A
- BIIB N/A
- Industry
- FE Electric Utilities: Central
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- FE Utilities
- BIIB Health Care
- Exchange
- FE Nasdaq
- BIIB Nasdaq
- Market Cap
- FE 24.5B
- BIIB 25.1B
- IPO Year
- FE N/A
- BIIB 1991
- Fundamental
- Price
- FE $39.89
- BIIB $149.02
- Analyst Decision
- FE Buy
- BIIB Buy
- Analyst Count
- FE 12
- BIIB 26
- Target Price
- FE $46.73
- BIIB $248.00
- AVG Volume (30 Days)
- FE 2.7M
- BIIB 1.6M
- Earning Date
- FE 02-06-2025
- BIIB 02-11-2025
- Dividend Yield
- FE 4.26%
- BIIB N/A
- EPS Growth
- FE 69.38
- BIIB 10.05
- EPS
- FE 1.55
- BIIB 11.06
- Revenue
- FE $13,257,000,000.00
- BIIB $9,607,500,000.00
- Revenue This Year
- FE $13.72
- BIIB N/A
- Revenue Next Year
- FE $4.41
- BIIB N/A
- P/E Ratio
- FE $25.73
- BIIB $13.47
- Revenue Growth
- FE 4.30
- BIIB N/A
- 52 Week Low
- FE $35.41
- BIIB $145.07
- 52 Week High
- FE $44.97
- BIIB $268.30
- Technical
- Relative Strength Index (RSI)
- FE 38.58
- BIIB 32.44
- Support Level
- FE $38.81
- BIIB $145.07
- Resistance Level
- FE $39.87
- BIIB $149.92
- Average True Range (ATR)
- FE 0.53
- BIIB 3.81
- MACD
- FE -0.04
- BIIB 0.05
- Stochastic Oscillator
- FE 38.71
- BIIB 22.51
About FE FirstEnergy Corp.
FirstEnergy is an investor-owned holding company with 10 regulated distribution utilities across six mid-Atlantic and Midwestern states. FirstEnergy also owns and operates one of the nation's largest electric transmission systems.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.